Open Access Full Text Article

#### CORRIGENDUM

# An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]

Citrome L, Graham C, Simmons A, et al. *Neuropsychiatr Dis Treat*. 2021;17:2885–2904.

The authors have advised there is an error in Figure 1C on page 2894. The key "OLZ/SAM" should read "Olanzapine + samidorphan 10 mg" and "Olanzapine" should read "Olanzapine + placebo".

Figure 1 legend, the text "Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12 in the combined OLZ/SAM groups (OLZ/SAM 5/10 mg, 10/10 mg, and 20/10 mg) versus olanzapine was the primary endpoint; only the olanzapine + placebo and olanzapine + samidorphan 10-mg groups are presented here to allow cross-study comparisons" should read "Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12, was the primary endpoint comparing the combined olanzapine + samidorphan groups versus the olanzapine + placebo group; to allow cross-study comparisons, only the olanzapine + samidorphan 10-mg and the olanzapine + placebo groups are presented here".

#### Neuropsychiatric Disease and Treatment

## **Dove**press

3135

### Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peerreviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal

https://doi.org/10.2147/NDT.S340597

Neuropsychiatric Disease and Treatment 2021:17 3135

Received: 22 September 2021 Accepted: 22 September 2021 Published: 15 October 2021 © 2021 Citrome et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs A2 and 5 of our Terms (https://www.dovepress.com/terms.php).